Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 1,042 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $65.96, for a total value of $68,730.32. Following the completion of the transaction, the executive vice president directly owned 50,660 shares of the company’s stock, valued at $3,341,533.60. This trade represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Callos also recently made the following trade(s):

• On Friday, December 5th, Andrew Callos sold 52,486 shares of Cytokinetics stock. The shares were sold at an average price of $65.95, for a total value of $3,461,451.70.

Cytokinetics Stock Down 2.3%

CYTK stock traded down $1.54 during trading on Monday, reaching $64.13. 1,497,507 shares of the company’s stock were exchanged, compared to its average volume of 1,905,409. Cytokinetics, Incorporated has a 1-year low of $29.31 and a 1-year high of $69.33. The firm has a market cap of $7.84 billion, a PE ratio of -10.20 and a beta of 0.58. The company’s fifty day moving average price is $61.93 and its 200-day moving average price is $46.47.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. Cytokinetics’s revenue for the quarter was up 318.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.36) earnings per share. As a group, sell-side analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CYTK. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research note on Monday, September 29th. JMP Securities reissued a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a report on Tuesday, September 2nd. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research report on Tuesday, September 2nd. Citigroup lifted their price target on Cytokinetics from $77.00 to $84.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Finally, Wall Street Zen lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $79.29.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CYTK. EverSource Wealth Advisors LLC boosted its stake in shares of Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 673 shares during the period. Quarry LP purchased a new position in Cytokinetics in the third quarter valued at about $30,000. Advisory Services Network LLC acquired a new position in Cytokinetics in the 3rd quarter worth about $32,000. Johnson Financial Group Inc. purchased a new stake in shares of Cytokinetics during the 3rd quarter worth about $40,000. Finally, Hantz Financial Services Inc. raised its stake in shares of Cytokinetics by 2,872.7% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,264 shares in the last quarter.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.